“Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)”, J of Skin, vol. 5, no. 6, p. s57, Nov. 2021, doi: 10.25251/skin.5.supp.57.